ABSTRACT We have constructed a simian virus 40 recombinant carrying a fragment of DNA from hepatitis B virus. Cultured monkey kidney cells infected with this recombinant produce hepatitis B surface antigen. The antigen is excreted into the culture medium as 22-nm particles with the same physical properties, antigenic composition, and constituent polypeptides as those found in the sera of patients with type B hepatitis.
Characterization ofthe life cycle and biology ofHBV has been hampered by its narrow host range, which is restricted to humans and a few other primates, and by its inability to grow in cultured cells. Recently, however, several groups have succeeded in cloning the viral genome in Escherichia coli phage A (4) and plasmid vectors (5, 6) and in determining its primary structure (7) (8) (9) . This has allowed the identification of a continuous 892-bp sequence that could encode surface antigen (7), a 549-bp sequence that may specify the core antigen (8) , and several additional open sequences of unknown function (9) .
Although the DNA sequence provides crucial structural information, it clearly is not sufficient to establish all of the HBV gene products or to indicate how these products interact during infection of the target cell. For this purpose it would be useful to develop a system for introducing defined portions ofthe viral genome into cultured cells. Simian virus 40 (SV40), a small DNA tumor virus that can lytically infect cultured monkey cells, provides a useful vector for this purpose. In this paper we describe the construction and propagation of a SV40 recombinant carrying a 1350-bp fragment of HBV DNA that includes the structural sequences for surface antigen. We show that monkey kidney cells infected with this recombinant synthesize surface antigen that is excreted into the culture medium as 22-nm particles. These results set an upper limit on the amount of HBV genetic information required for 22-nm particle formation and demonstrate the feasibility ofusing SV40 recombinants to study HBV gene expression in cultured primate cells.
MATERIALS AND METHODS
The following methods have been described: general procedures for the construction of recombinant plasmids and viruses (10) ; growth of African green monkey kidney cells and propagation of virus stocks (11); preparation of plasmid (12) and intracellular SV40 DNA (13); analysis of DNA by restriction endonuclease cleavage (11) and agarose gel electrophoresis (14, 15) ; and transformation of EK2 Escherichia coli strain HB101 (16) . Restriction endonucleases and T4 DNA ligase were purchased from Bethesda Research Laboratories (Rockville, MD) and reaction conditions were according to the supplier.
The source of HBV DNA was plasma, subtype adw, from an HBsAg-positive donor. Dane particles were purified by the method ofRobinson (17) and incubated in the endogenous DNA polymerase reaction (18) with all four deoxynucleotide triphosphates prior to DNA extraction.
The 22-nm form of HBsAg was purified from the plasma of chronic carriers as described (19) . Hyperimmune guinea pig antiserum to HBsAg/ad (V801-502-058) was from Research Resources Branch (National Institute of Allergy and Infectious Diseases) and monospecific antibodies to the HBs/a and HBs/ d determinants were prepared from this serum by affinity chromatography (3). Fluorescein isothiocyanate-conjugated rabbit anti-guinea pig IgG was obtained from Cappel Laboratories (Cochranville, PA). Radioimmunoassays for hepatitis B core antigen (20) , 8 antigen (21), and e antigen (HBeAg test kit, Abbott Laboratories) have been described. HBsAg was detected by the Ausria II radioimmunoassay (Abbott Laboratories) and quantitated by a parallel-line assay with a known standard (BoB HBsAg/adw vaccine, reference lot 1, 40 jig/ml). The d/y subtype of HBsAg was determined by the competition radioimmunoassay method of Hoofnagle (22) . All experiments requiring physical containment level P3 were performed at the certified P3 facility of the Georgetown University Division of Molecular Virology and Immunology of ligation assay buffer, and treated with 4 units of T4 DNA ligase for 5 hr at 14°C. This mixture was used to transform E. coli HB101, and a pBR322-HBV clone was identified by colony hybridization (23) . DNA from this clone was cleaved with BamHI and the 1350 bp fragment containing the HBsAg coding region was purified by preparative electrophoresis through a 0.8% agarose gel (15) ; subcloned in pBR322 and reisolated by electrophoresis.
Step B. pBR322-SV40 was prepared, as described (24) , by cleavage with BamHI/EcoRI, treatment with ligase, and cloning in E. coli.
Step C. pBR322-HBV was then ligated to BamHI-cleaved pBR322-SV40 DNA and cloned in E. coli as described above.
Step D. Hae II cleavage of the resulting pBR322-SV4O-HBV "double recombinant" DNA generated the 4950-bp linear SVHBV DNA fragment that was used to infect monkey kidney cells. (Fig. 2) , whereas uninfected cells and cells infected with wild-type SV40 were negative. Quantitative radioimmunoassays showed that a culture of 2 x 107 cells produced a total of 2.5 ,ug of fBsAg. Of this, 40% was found in the medium and 60% was released from the cells by freeze-thawing and sonication. Subtype analysis (22) showed that SVHBV-HBsAg had the same antigenic composition (d+, y -) as the antigen from the original donor of the HBV DNA. SVHBV-infected cells were negative for HBcAg and 8 antigen by immunofluorescence. The culture medium was negative (P/N<2. 1) for HBcAg, HBeAg, and B antigen by solid-phase radioimmunoassay.
The HBsAg Is Secreted from Monkey Kidney Cells as a Particle. SVHBV-HBsAg found in the tissue culture fluid is a 22-nm particle whose physical characteristics are the same as those ofthe particles found in human serum. Isopycnic banding in CsCl of SVHBV-HBsAg revealed a buoyant density value (1.2 g/cm3) identical to that of purified HBsAg run in parallel (Fig. 3A) . The SVHBV-HBsAg material was further characterized by rate zonal centrifugation (Fig. 3B) . Most ofthe SVHBVspecific antigen sedimented as a particle indistinguishable from the 22-nm particles found in human sera. Examination of the antigen by electron microscopy of the pooled, concentrated peak fractions from the sucrose gradient (Fig. 3 Inset) 
FIG. 3. Biophysical properties and appearance of HBsAg from SVHBV-infected monkey kidney cells. (A)
The medium ofmonkey kidney cells, harvested 72 hr after infection with SVHBV, was clarified for 10 min at 1000 x g to remove cells and a 0.5-ml sample was layered onto a five-step gradient (1.1-1.6 g/cm3) of CsCl in 0.01 M Tris HCl (pH 7.4) in a cellulose nitrate tube of the Spinco SW 41 rotor. The gradient was centrifuged for 18 hr at 40C and 34,000 rpm. Fractions (0.5 ml) were collected by bottom puncture and assayed for HBsAg by a commercial radioimmunoassay (Ausria II); results are expressed as the ratio of 125I cpm in the sample (P) to the negative control (N; 93 cpm). CsCl density was determined by refractometry. (B) A 7-ml sample of medium from the SVHBV-infected cells was layered onto a 5-ml twostep gradient (1.2 and 1.5 g/cm3) of CsCl in 0.01 M Tris HCl (pH 7.4) and centrifuged for 18 hr at 40C and 34,000 rpm in an SW 41 rotor.
Fractions (1 ml) were collected by bottom puncture and assayed for HlsAg (at 1:10 dilution) by Ausria II; CsCl density was measured by refractometry. HBsAg was recovered in a single fraction at approximately 1.2 g/cm3 (P/N = 65 at 1:10 dilution). This fraction was dialyzed extensively against 0.85% NaCl/0.01 M phosphate, pH 7.4, and a 0.5-ml sample was layered onto an 11-ml linear gradient of 10-30% (wt/wt) sucrose in the buffered saline with a cushion of 0.5 ml of 66% (wt/wt) sucrose in buffered saline. After centrifugation for 4.5 hr at 35 ,000 rpm and 40C in an SW 41 rotor (22 x 1010 w t), 0.5-ml fractions were collected by bottom puncture and assayed for HBsAg ( The peak fractions (Fig. 3B, fractions 15-17 , 300 1d each) were pooled and concentrated 15-fold by pelleting. The concentrate was iodinated by the chloramine-T procedure (28) and further purified by rate zonal centrifugation in sucrose. A standard HBsAg/ad preparation isolated from human serum was iodinated and purified in parallel. and by both ofthe monospecific antibodies. NaDodSO4 gel electrophoresis of the denatured and reduced precipitates revealed two predominant polypeptides (P1 and P2) with the same mobilities as those isolated from human serum (Fig. 4A) . These proteins are thought to be identical except that P2 is glycosylated. In addition, the iodinated SVHBV-HBsAg contained at least one of the minor polypeptides of higher molecular weight (P5).
In a companion experiment, SVHBV-specific proteins were biosynthetically labeled by incubating the infected cells with [3S]methionine for 4 hr late in the 'lytic cycle. Direct examination of the medium from SVHBV-infected cells revealed two proteins with the same mobilities as P1 and P2 (Fig. 4B) , both of which were precipitated by anti-HBs antiserum (Fig. 4C) . In contrast, no such proteins were found in the medium from uninfected or wild-type SV40-infected cells. This experiment also demonstrated that HBsAg is actively excreted rather than merely released by cell lysis because only a subpopulation of the total cell proteins was found in the medium. DISCUSSION We have described the construction of an SV40-HBV recombinant that retains about 70% of the SV40 genome and 40% of the HBV genome. This hybrid virus is replicated and packaged into SV40 virions.in cultured monkey kidney cells, the permissive host for SV40, that have been coinfected with a complementing SV40 helper virus. The expression of the inserted HBV sequences was examined by both immunological and biochemical techniques. This showed that the recombinant directs the synthesis of surface antigen but no other known HBV-specific antigens. Furthermore, blocking assays and immunoprecipitation with monospecific antibodies demonstrated that the SVHBV-derived HBsAg had the same subtype (ad) as the antigen .from the original donor of the HBV DNA. Because the SVHBV recombinant was derived from a cloned plasmid containing only the 1350-bp BamHI fragment of HBV, these observations demonstrate that both group-and subtype-specific determinants of HBsAg are encoded within a limited portion of the viral genome.
HBsAg from monkey cells contains the same major polypeptides (P1 and P2), with the same Pl-to-P2 ratio, as HBsAg derived from human serum. Because P2 represents a glycosylated form ofP1, it appears that the posttranslational modification of this HBV gene product is not unique to liver cells. At least one minor polypeptide ofhigher molecular weight (P5) was also seen in extrinsically labeled HBsAg but not in biosynthetically labeled HBsAg. Interestingly, the size of this polypeptide HBsAg/ad. The antigens were radioiodinated and precipitated as described in Table 1 , solubilized in 2% NaDodSO4/2% 2-mercaptoethanol, and electrophoresed through a NaDodSO4/7.5% acrylamide gel (25) (49,000) represents the upper limit of the coding capacity of the inserted HBV fragment. The HBsAg encoded by SVHBV is excreted into the culture medium as 22-nm particles with the same buoyant density, sedimentation properties, and appearance as the particles from human serum. These particles are produced at a rate of 2.5 Ag/ 107 cells per 2 days or approximately 3 x 104 particles per infected cell per day. This compares favorably with HBsAg production by the Alexander cell line (31) derived from a human hepatocellular carcinoma. We conclude that monkey kidney cells possess all of the functions required for particle formation and that the failure of HBV to grow in tissue culture is not due to a' block at this stage of the viral life cycle.
Recently, Dubois et al. (32) used the thymidine kinase cotransformation technique to obtain mouse L cell lines that excrete 22,nm particles. However, in those experiments, HBsAg expression depended upon the presence of two complete tandem copies of the HBV genome rather than upon a defined subfragment. The HBV surface antigen gene has also been expressed in E. coli as part of a 138,000-dalton HBsAg-f3-galactosidase fusion polypeptide (33) . Not surprisingly, this hybrid antigen is not glycosylated, assembled into particles, or ex-.'Micrabiology: Moriarty et al.
creted from the bacterial host. Thus, it seems likely that animal cell expression systems will provide a useful complement to the prokaryotic systems in those instances in which the final gene product is modified and assembled into a complex biological structure.
We do not know to what extent expression ofthe surface antigen gene in SVHBV depends upon SV40 regulatory signals as compared to HBV signals. The vector used in this experiment retains the SV40 late region promoter, the late 19S mRNA splice junction, and the late region polyadenylylation signal. On the other hand, Hamer et al. (24, 34, 35) have shown, using the chromosomal mouse a-and 81-globin genes, that the genomic signals for transcription initiation and RNA processing can be recognized in the SV4O-monkey cell system. To resolve this question, it will be necessary to study the structures ofthe RNAs encoded by SVHBV andrmutants derived from it.
The ability to propagate defined portions ofthe HBV genome in cultured primate cells raises several interesting experimental opportunities. In addition to the obvious possibility of vaccine production, it should be feasible to construct viruses that encode useful diagnostic reagents such as surface antigen peptides bearing single, highly specific immunological determinants. SV40-HBV hybrids might also be useful for identifying new HBV gene products-e.g., nonstructural proteins that are not excreted into the serum. Finally, the availability of SV40-HBV recombinants provides an experimental system with which to investigate various mechanisms for the persistence and pathogenicity of HBV in liver cells.
